Comparative Study of Botox Brands for Hyperhidrosis in Brazil

Understanding Hyperhidrosis

Hyperhidrosis is a medical condition characterized by excessive sweating that surpasses normal levels. This condition can manifest in two forms: generalized or focal. There are various surgical and non-surgical treatment options available, boasting efficacy rates between 90% to 95%.

Role of Botulinum Toxin Type-A

Among the various treatments for focal hyperhidrosis, Botulinum toxin type-A (BTX-A) has emerged as one of the most effective. BTX-A is a potent neurotoxin derived from the bacterium Clostridium botulinum, consisting of eight purified protein complexes. For treating focal hyperhidrosis, BTX-A is injected beneath the skin, where it prevents the release of acetylcholine, a neurotransmitter that stimulates sweat glands.

Study Overview

In Brazil, researchers undertook a six-month clinical study to compare the effectiveness of five commercially available brands of BTX-A for treating excessive sweating. The brands included Botox, Botulift, Dysport, Xeomin, and Prosigne. The primary measure of efficacy was the reduction in the area of sweating, referred to as the sweating inhibition halo (SIH).

Study Methodology

The study involved 25 adult female participants who received injections in the muscles and bones of the back with BTX-A products in two different dosages: 100 units (100UI) and 500 units (500UI), reconstituted at a ratio of 1:2.5. The injections were administered at five concentrations (1:2.5U, 2:5U, 3:7.5U, 4:10U, and 5:12.5U). A starch-iodine test was conducted at intervals of 30, 60, 90, 120, 150, and 180 days to measure the largest diameter of SIH.

Study Findings

The results indicated that higher dosages of BTX-A led to larger SIH across all products. The Botox products—namely Botox, Botulift, Dysport, and Prosigne—exhibited similar SIH results, with minor variations noted at certain doses and time points. In contrast, Xeomin was identified as having the smallest SIH across all doses and timeframes.

Study Limitations and Implications

One notable limitation of this study was the exclusive participation of female subjects. Nonetheless, the findings provide valuable insights for medical professionals regarding the comparative efficacy of different Botox brands for hyperhidrosis treatment. This knowledge can assist healthcare providers in selecting the most appropriate Botox treatment based on the specific area of concern and its distribution in risk zones.

Further Exploration of Botox Applications

For additional information on the medical uses of Botox, please refer to other resources available on this topic.

References

da Costa A, Pegas Pereira ES, Pereira MO, Dos Santos FBC, Fávaro R, de Matos LS, Tannous TS, Duarte COP, Pereira CS. Six-Month Comparative Analysis Monitoring the Progression of the Largest Diameter of the Sweating Inhibition Halo of Different Botulinum Toxins Type-A. Aesthet Surg J. 2018.